Mechanisms of the influence of «Ozagrel» on platelet aggregation
https://doi.org/10.24884/1682-6655-2012-11-3-76-80
Abstract
Drug that inhibits thromboxane A2 synthesis is used to reduce platelet aggregation. The aim of this study was to compare the effects of a thromboxane synthetase inhibitor ("Ozagrel") and a cyclo-oxygenase (COX) inhibitor (acetylsalicylic acid) on platelet aggregation. The techniques used in this in vitro study were platelet aggregometry in whole blood. The effect of specific blockage of thromboxane synthetase "Ozagrel" can surpass the effect of acetylsalicylic acid in inhibiting the collagen and epinephrine-induced platelet aggregation. Thus, the combination of a thromboxane synthetase inhibitor and of a cyclo-oxygenase inhibitor may have some clinical perspective.
About the Authors
L. V. Vasina
V. A. Almazov Federal Center of Heart, Blood and Endocrinology
Russian Federation
Russian Federation
O. S. Veselkina
ZAO «Vertex»
Russian Federation
Russian Federation
N. N. Petrishchev
V. A. Almazov Federal Center of Heart, Blood and Endocrinology
Russian Federation
Russian Federation
References
1. Бокарев, И. Н. К 125-летию ацетилсалициловой кислоты / И. Н. Бокарев, Л. В. Попова // Rational Pharmacother. Card. - 2011. - Vol. 7. - № 4. - Р. 492-500.
2. Сибиряк, C. B. Иммунотропная активность производных азолов и их конденсированных гетероциклических систем: обзор / С. В. Сибиряк [и др.] // Хим. фарм. журн. - 1990. - Т. 24. - Вып. 11. - С. 19-24.
3. Шитикова, А. С. Механизм действия ацетилсалициловой кислоты на процессы гемостаза / А.С. Шитикова // Мед. акад. журн. - 2003. - № 1. - С. 23-35.
4. Шитикова, А. С. Тромбоцитопатии, врожденные и приобретенные / А. С. Шитикова; под ред. Л. П. Папаян, О. Г. Головиной. - СПб.: ИИЦ ВМА, 2008. - 320 с.
5. Antithrombotic effects of FK41 novel nonpeptide platelet GP IIb/IIIa antagonist, in a guinea pig photochemically induced middle cerebral artery thrombosis model: comporison with ozagrel and argatroban / A. Moriguchi [et al] // JPET. -2004. - Vol. 308. - № 3. - Р. 1094-1101.
6. Arii, К. The effect of ozagrel sodium on photochemical thrombosis in rat: therapeutic window and combined therapy with heparin sodium / K. Arii, H. Igarashi, T. Arii, Y. Katayama // Life Sciences. - 2002. - Vol. 71. - № 25. - Р. 2983-2994.
7. Bhatt, D. L. Scientific and therapeutic advances in antiplatelet therapy / D. L. Bhatt, E. J. Topol // Nature Reviews Drug Discovery. - 2003. - № 2. - Р. 15-28.
8. Cardinal, D. C. The electronic aggregometer: a novel device for assessing platelet behavior in blood / D. C. Cardinal, R. J. Flower // J. Pharm. Meth. -1980. - № 1. - Р. 135-158.
9. Defreyn, G. A thromboxane synthetase inhibitor reorients endoperoxide metabolism in whole blood towards prostacyclin and prostaglandin E2 / G. Defreyn, H. Deckmyn, J. Vermylen // Thromb Res. - 1982. - № 26. - Р. 389-400.
10. Effect of ozagrel, a selective thromboxane A2-synthetase inhibitor, on cerebral infarction in rats. Comparative study with norphenazone, a free-radical scavenger / T. Imamura [et al[ // Arzneimittel-Forschung. - 2003. - Vol. 53. - № 10. - P. 688-694.
11. Effects of the selective inhibition of platelet thromboxane synthesis on the platelet-subendothelium interaction / J. P. De La Cruz [et al] // British. J. Pharm. - 2002. - № 137. - Р. 1082-1088.
12. Effects of thromboxane A2 synthase inhibitors (CV-4151 and ozagrel), aspirin, and ticlopidine on the thrombosis caused by endothelial cell injury / Z. Terashita [et al] // Thromb Res. - 1995. -Vol. 77. - № 5. - P. 411-421.
13. Heterocyclic GABA analogues. Displacement of radiolabelled 3H-GABA from rat brain membrane preparations / M. Varasi [et al] // Farmaco. - 1987. - Vol. 42. - № 6. - P. 425-435.
14. Iizuka, K. Highly selective inhibitors of thromboxane synthetase. 1. Imidazole derivatives / K. Iizuka [et al] // J. Med. Chem. - 1981. - Vol. 24. - № 10. - P. 1139-1148.
15. Kamijo, T. An improved and convenient procedure for the synthesis of 1-substituted imidazoles / T. Kamijo [et al] // Chem. Pharm. Bull. - 1983. - Vol. 31. - № 4. - P. 1213-1221.
16. Lefkovits, J. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine / J. Lefkovits, E. F. Plow, E. J. Topol // N. Engl. J. Med. - 1995. - Vol. 332. - P. 1553-1559.
17. Thromboxane A2 synthetase inhibitor plus low dose aspirin: can it be a salvage treatment in acute stroke beyond thrombolytic time window / G. Hwan An [et al] // J. Korean. Neurosurg. soc. - 2011. - № 50. - Р. 1-5.
Review
For citations:
Vasina L.V., Veselkina O.S., Petrishchev N.N. Mechanisms of the influence of «Ozagrel» on platelet aggregation. Regional blood circulation and microcirculation. 2012;11(3):76-80. (In Russ.) https://doi.org/10.24884/1682-6655-2012-11-3-76-80
Views:
293
Email this article 
